← Leaderboards
Ling Gao
Veterans Health Administration
$1,511,555
Attributed
$1,511,555
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $384.9K · FY2020–25$500K$375K$250K$125K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,511,555 · 1
VA$0 · 2
By mechanism
R01$1,511,555 · 1
I01$0 · 2
Top collaborators
No co-investigators on record.
Most similar at Veterans Health Administration
Same institution · by research overlap
- Venkateshwar G Keshamouni$2,783,665
- Dandan Sun$18,130,400
Others in their field
Other Emerging Leaders on “Response”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$195,683,539
- Kimberly Smith · Ppd Development Lp$115,671,664
- Paul F Gallagher · Woods Hole Oceanographic Institution$92,619,872
- Kevin Urdahl · Seattle Children'S Hospital$84,741,409
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,439,892
- Ted Ross · University Of Georgia$70,992,558
Research focus
ResponseTargeted TreatmentNeuroendocrine CancerResistanceSolid NeoplasmSurvival RateClinically RelevantMouse ModelPharmaceutical PreparationsReportingMelanomaSkin CancerSuccessMalignant NeoplasmsAdvanced DiseaseBiological MarkersImmuneMerkel Cell CarcinomaImmunotherapyImmune SystemPositioning AttributeCell LineIn VivoTreatment Efficacy
Grant awards (11)
Identifying novel therapies targeting Merkel cell carcinoma and tumor microenvironment$384,870
R01 · FY2025 · CA · contact PI
Unravel the role of CD276 and determine efficacy of CD276-targeted therapy on Merkel cell carcinoma progression and metastasis$0
I01 · FY2025 · VA · contact PI
Identifying novel therapies targeting Merkel cell carcinoma and tumor microenvironment$362,472
R01 · FY2024 · CA · contact PI
Unravel the role of CD276 and determine efficacy of CD276-targeted therapy on Merkel cell carcinoma progression and metastasis$0
I01 · FY2024 · VA · contact PI
Identifying novel therapies targeting Merkel cell carcinoma and tumor microenvironment$379,343
R01 · FY2023 · CA · contact PI
Preclinical investigation of PI3K inhibition and immune checkpoint blockade combination therapy for treatment of Merkel cell carcinoma using humanized mouse models$0
I01 · FY2023 · VA · contact PI
Unravel the role of CD276 and determine efficacy of CD276-targeted therapy on Merkel cell carcinoma progression and metastasis$0
I01 · FY2023 · VA · contact PI
Identifying novel therapies targeting Merkel cell carcinoma and tumor microenvironment$384,870
R01 · FY2022 · CA · contact PI
Preclinical investigation of PI3K inhibition and immune checkpoint blockade combination therapy for treatment of Merkel cell carcinoma using humanized mouse models$0
I01 · FY2022 · VA · contact PI
Preclinical investigation of PI3K inhibition and immune checkpoint blockade combination therapy for treatment of Merkel cell carcinoma using humanized mouse models$0
I01 · FY2021 · VA · contact PI
Preclinical investigation of PI3K inhibition and immune checkpoint blockade combination therapy for treatment of Merkel cell carcinoma using humanized mouse models$0
I01 · FY2020 · VA · contact PI